De-risk your program with evidence-based secondary pharmacology insights Blog Post
安全性问题约占药物项目损耗的四分之一，可能源于初级药理学或次要药效学作用。To address secondary pharmacology, researchers typically screen…
Stakeholder perspectives: current and potential benefits Blog Post
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than…
Strengths and opportunities for HTAs and market access in Europe through case studies Blog Post
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than…
Similarities and differences between SNDS and other claim databases Blog Post
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than…
Overview of SNDS and the key working practices to access the database and ongoing SNDS developments Blog Post
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than…
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS) Blog Post
Watch this presentation to learn • Overview of the SNDS and the key working practices to access the database and ongoing SNDS developments • Similarities and differences between SNDS and…
Maximizing Oligonucleotide Therapeutic Development: How They Work Blog Post
This is the first of three blog posts discussing best practices for developing oligonucleotides. Interest in oligonucleotide therapies, which are composed of short strands of DNA or RNA, is growing…
